ibandronate sodium

DRUG5 trials

Sponsors

Cancer Research UK, SWOG Cancer Research Network, Wales Cancer Trials Unit, Dr. Reddy's Laboratories Limited

Conditions

Breast CancerHealthyHypercalcemia of MalignancyMetastatic CancerPainProstate Cancer

Phase 1

Bioequivalence Study of Ibandronate Sodium Tablets 150 mg Under Fasting Condition

CompletedNCT01627886

Dr. Reddy's Laboratories LimitedHealthy

Start: 2008-09-30End: 2008-10-31Updated: 2012-06-28

Phase 3

Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone Pain

CompletedNCT00082927

Cancer Research UKMetastatic Cancer, Pain, Prostate Cancer

Start: 2003-04-30End: 2011-07-31Target: 580Updated: 2013-06-26

S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.

CompletedNCT00127205

SWOG Cancer Research NetworkBreast Cancer

Start: 2005-07-31End: 2021-03-29Updated: 2021-07-02

Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer

Wales Cancer Trials UnitBreast Cancer, Hypercalcemia of Malignancy, Metastatic Cancer

Start: 2006-01-31End: 2015-10-31Updated: 2013-03-13

Unknown Phase

S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307

WithdrawnNCT00873808

SWOG Cancer Research NetworkBreast Cancer

Start: 2008-10-31End: 2010-02-28Updated: 2013-04-10

Related Papers

Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307).

2020-09-1523 citations

Abstract P2-18-02: Fractures in women with breast cancer receiving high-dose bisphosphonates to prevent breast cancer metastases as part of the SWOG S0307 trial (ClinicalTrials.gov Identifier: NCT00127205)

Cancer Research2020-02-15

Factors associated with osteonecrosis of the jaw in women with breast cancer receiving high-dose bisphosphonates to prevent breast cancer metastases as part of the SWOG 0307 trial.

Journal of Clinical Oncology2019-05-201 citations

The use of randomisation-based efficacy estimators in non-inferiority trials.

2017-03-093 citations

Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307.

Journal of Clinical Oncology2015-05-2023 citations

SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: Comparison of toxicities and patient-stated preference for oral versus intravenous delivery.

Journal of Clinical Oncology2014-05-2014 citations

Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.

2013-12-1170 citations